Paxmedica announces positive top line results from the pax-101 (intravenous suramin) phase 3 african sleeping sickness study, pax-hat-301

Tarrytown, ny, july 24, 2023 (globe newswire) -- via newmediawire -- paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced positive top line data for the company's pax-hat-301 retrospective analysis of suramin treatment for stage 1 trypanosoma brucei rhodesiense human african trypanosomiasis (s1 tbr hat).
PXMD Ratings Summary
PXMD Quant Ranking